Journal of the American Academy of Dermatology
Etanercept: An overview☆
Section snippets
Etanercept structure and mechanism of action
Etanercept is a fully human dimeric fusion protein consisting of the extracellular ligand-binding domain of the human 75 kilodalton (kDa) TNF-α receptor linked to the Fc portion of human immunoglobulin G1 (IgG1). Despite the presence of an Fc region, etanercept does not promote complement-mediated cell lysis in vitro.3 Etanercept has been shown to have a very low (<2%) rate of immunogenicity when studied in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and congestive heart
Etanercept safety
The safety of etanercept has been demonstrated in more than 130,000 patient-years of exposure in both controlled clinical trials and in post-marketing surveillance. In controlled trials, the only adverse event that occurred significantly more frequently in patients treated with etanercept compared to placebo was mild to moderate injection site reactions (erythema and/or itching, pain, or swelling), in approximately 37% of patients receiving etanercept.3 These reactions tended to occur in the
Conclusion
Etanercept has demonstrated consistent efficacy in the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, RA, and JRA. Research on the potential future use of etanercept in other inflammatory diseases is ongoing. The rapid and significant clinical responses to this agent underscore both the central role of TNF-α in contributing to the pathology of these diseases, and the potent inhibitory effects of etanercept on its ability to do so. Etanercept is well tolerated by both
References (29)
- et al.
Etanercept in the treatment of psoriatic arthritis and psoriasisa randomised trial
Lancet
(2000) - et al.
The active form of tumor necrosis factor is a trimer
J Biol Chem
(1987) - et al.
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Lancet
(2002) - et al.
Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL)results of a phase 3 multicenter clinical trial
Arthritis Rheum
(2001) - Etanercept [package insert]. Seattle, WA: Immunex Corporation and Wyeth-Ayerst Pharmaceuticals;...
- Moreland LW, Cohen S, Fleischmann RM, Baumgartner SW, Schiff MH, Burge DJ. Safety and efficacy of up to 5 years of...
- et al.
Inflammatory skin diseases, T cells, and immune surveillance
N Engl J Med
(1999) - et al.
Mechanisms for modulating TNFα in immune inflammatory disease
Curr Opin Drug Discov Devel
(2001) - et al.
Cytokines in psoriasis
Int J Dermatol
(1999) The immunologic basis for the treatment of psoriasis with new biologic agents
J Am Acad Dermatol
(2002)
The cytokine network in psoriasis
Arch Dermatol
Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptorevidence for tumor necrosis factor- alpha induced receptor aggregation
Biochemistry
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
J Exp Med
Cited by (176)
High-yield vesicle-packaged recombinant protein production from E. coli
2023, Cell Reports MethodsSodium dodecyl sulfate-capillary gel electrophoresis with native fluorescence detection for analysis of therapeutic proteins
2022, Journal of Pharmaceutical and Biomedical AnalysisCytokine Therapy
2022, Encyclopedia of Infection and ImmunityBiological macromolecules as immunomodulators
2021, Biological Macromolecules: Bioactivity and Biomedical ApplicationsA data-driven methodology towards evaluating the potential of drug repurposing hypotheses
2021, Computational and Structural Biotechnology JournalCitation Excerpt :Only the association with the last one exceeds DISNET’s average with GDA scores of 0.7 and 0.4, respectively. In RA, excessive production of TFN-α, in the synovial fluid and the serum, causes chronic inflammation, tissue damage, and immoderate keratinocyte proliferation [59]. Otherwise, in patients with severe asthma, TFN-α high levels have been found in bronchial biopsies and induced sputum [60].
Therapeutic Fusion Proteins
2024, AAPS Journal
- ☆
Funding sources: None.
Disclosure: Drs Cather and Goffe have participated in clinical trials involving Enbrel. Dr Goffe is involved in trials funded by Immunex (now Amgen), Biogen, Genentech, Corixa, IDEC, Boehringer-Ingelheim, ISIS, Fujisawa, and Bristol Meyers. Dr Goffe is on the speaker’s bureau for Amgen; however, he is not a paid consultant.